HCA Corporation
HCA
$498.66
+0.25%
HCA Healthcare, Inc. is a leading healthcare services company operating the largest collection of acute-care hospitals and outpatient facilities in the United States, with a portfolio of 190 hospitals and over 2,500 sites across 19 states and a small international presence. The company is a dominant market leader in the for-profit hospital sector, distinguished by its scale, geographic diversification, and integrated network of care delivery. The current investor narrative centers on the company's demonstrated operational resilience and strong financial performance, as highlighted by recent earnings, against a backdrop of ongoing debates regarding regulatory pressures and the long-term demographic tailwinds from an aging American population.…
HCA
HCA Corporation
$498.66
Related headlines
Investment Opinion: Should I buy HCA Today?
Rating & Thesis: HCA is a Hold. The stock presents a balanced risk/reward profile where strong fundamentals are counterbalanced by near-term technical weakness and sector-specific risks, making it prudent to await a better entry point or clearer catalyst despite generally positive analyst sentiment.
Supporting Evidence: The recommendation is supported by four key data points: 1) The forward PE of 14.89x is reasonable but not deeply discounted, 2) Revenue growth is solid at 6.72% YoY, 3) Profitability is high with a net margin expanding to 9.62%, and 4) Free cash flow generation is exceptional at $7.69B TTM. However, the stock's high beta of 1.37 and recent -7.78% monthly decline signal elevated near-term volatility and investor caution that tempers the bullish fundamental case.
Risks & Conditions: The two biggest risks are a deterioration in the regulatory/payment environment and a broader market sell-off that disproportionately hits high-beta stocks like HCA. This Hold rating would upgrade to a Buy if the PE compresses further towards 13x on non-fundamental weakness, or if the price establishes firm support above $500 on sustained volume. It would downgrade to a Sell if quarterly revenue growth decelerates below 4% or if operating margins contract by 200+ basis points. The stock is currently fairly valued relative to its own history and sector, pricing in its growth and risks appropriately.
Sign up to view all
HCA 12-Month Price Forecast
The AI assessment is neutral with medium confidence. HCA is a fundamentally strong company caught in a volatile stock. Its leading scale, profitability, and cash flow are undeniable strengths, but these are fully appreciated by the market at the current valuation. The high beta and recent technical breakdown suggest near-term headwinds. The stance would upgrade to bullish on a pullback to the low $470s, offering a better margin of safety, or on a confirmed breakout above $540 with strong volume. It would turn bearish if the stock breaks below $467 support on a weekly closing basis, signaling a deeper correction is underway.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HCA Corporation's 12-month outlook, with a consensus price target around $648.26 and implied upside of +30.0% versus the current price.
Average Target
$648.26
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$399 - $648
Analyst target range
Analyst coverage for HCA is extensive and leans bullish, as evidenced by a series of recent 'Buy' or 'Outperform' ratings from firms including TD Cowen, Mizuho, UBS, and Deutsche Bank in early 2026. The consensus sentiment is positive, supported by the company's operational strength and shareholder returns, though some firms like JP Morgan and Wells Fargo maintain a 'Neutral' or 'Equal Weight' stance, likely reflecting balanced views on regulatory risks. While a precise average target price and implied upside are not provided in the dataset, the high level of institutional interest and generally favorable ratings indicate strong professional conviction in the stock's prospects. The target price range, implied by the estimated EPS range of $48.21 to $50.93, would translate to a valuation range based on the forward PE, signaling the breadth of analyst expectations. The high end of estimates likely incorporates scenarios of continued market share gains and margin resilience, while the low end may factor in potential headwinds like reimbursement pressures or economic slowdowns. The active and recent rating actions from multiple major firms, all reaffirming positive views, suggest a stable and confident analyst community, reducing the uncertainty typically associated with a wide target spread.
Bulls vs Bears: HCA Investment Factors
The evidence currently tilts bullish, grounded in HCA's demonstrable operational strength, margin expansion, and robust cash generation. The bear case is primarily technical and macro-sensitive, focusing on recent price weakness and sector risks. The most critical tension in the investment debate is between the company's strong fundamental performance (6.72% revenue growth, 9.62% net margin) and its elevated volatility (beta 1.37) combined with regulatory uncertainty. The resolution of this tension—whether solid execution can consistently outweigh policy fears and market sentiment swings—will determine the stock's trajectory.
Bullish
- Strong Profitability & Margin Expansion: HCA's Q4 2025 net margin of 9.62% improved from 7.86% in Q4 2024, demonstrating effective cost control and operating leverage. The company's operating margin of 16.29% and gross margin of 41.90% are robust for the capital-intensive hospital sector, supporting high returns on assets of 12.44%.
- Robust Free Cash Flow Generation: The company generates substantial cash, with TTM free cash flow of $7.69 billion. This strong cash flow provides ample capacity for debt service (interest coverage of 5.56x), shareholder returns, and strategic investments, underpinning financial resilience.
- Consistent Revenue Growth Trajectory: HCA delivered 6.72% YoY revenue growth in Q4 2025, with sequential quarterly increases from $18.32B to $19.51B. This steady top-line expansion, driven by its dominant scale across 190 hospitals, provides a stable foundation for earnings growth.
- Attractive Valuation Relative to History: Trading at a trailing PE of 15.88x, HCA is well below its recent historical high of 20.79x from Q3 2024. The forward PE of 14.89x suggests the market is not pricing in aggressive growth, offering a reasonable entry point within its own valuation context.
Bearish
- High Volatility & Recent Technical Weakness: With a beta of 1.37, HCA is 37% more volatile than the market, amplifying downside risk. The stock is down -7.78% over the past month, underperforming the S&P 500 by -8.24%, signaling a potential breakdown from its uptrend and investor caution.
- Leveraged Balance Sheet & Tight Liquidity: The debt-to-equity ratio is -8.33 due to negative shareholder equity from buybacks, indicating a leveraged capital structure. The current ratio of 0.83 shows relatively tight liquidity for meeting short-term obligations, which could pressure operations if financing costs rise.
- Regulatory & Reimbursement Risk: As a for-profit hospital leader, HCA is highly exposed to changes in government healthcare policy (Medicare/Medicaid) and reimbursement rates. This persistent regulatory overhang can compress margins and create earnings volatility, a key reason some analysts maintain Neutral stances.
- Valuation Premium to Sector Peers: While its trailing PE of 15.88x is below its own highs, it trades at a premium to many hospital peers. This premium, justified by scale and execution, is vulnerable to compression if growth decelerates or sector multiples contract due to macro or policy shifts.
HCA Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a robust 1-year price change of +47.91%, significantly outperforming the broader market. As of the latest close at $495.47, the price is trading approximately 74.8% of its 52-week range ($314.43 to $556.52), positioning it closer to the high end, which reflects strong investor confidence but also suggests potential for overextension if momentum wanes. Recent short-term momentum, however, shows signs of deceleration and divergence from the longer-term trend; the stock is down -7.78% over the past month and up only +4.96% over the past three months, indicating a significant pullback from recent highs and potential consolidation. This divergence could signal a healthy correction within the broader uptrend or a pause as the stock digests its substantial prior gains, with the negative relative strength of -8.24% over one month underscoring recent underperformance versus the S&P 500. Key technical support is anchored near the 52-week low of $314.43, though more immediate support lies around recent pullback lows in the $467-$471 range, while resistance is clearly defined by the 52-week high of $556.52. A breakout above this high would signal a resumption of the primary bullish trend, whereas a sustained breakdown below the $467 level could indicate a deeper correction is underway. The stock's beta of 1.37 confirms it is approximately 37% more volatile than the market, a critical factor for risk-aware investors given its recent price swings and the sector's sensitivity to policy news.
Beta
1.37
1.37x market volatility
Max Drawdown
-14.2%
Largest decline past year
52-Week Range
$314-$557
Price range past year
Annual Return
+46.4%
Cumulative gain past year
| Period | HCA Return | S&P 500 |
|---|---|---|
| 1m | -6.4% | +4.9% |
| 3m | +4.1% | +0.6% |
| 6m | +18.8% | +5.1% |
| 1y | +46.4% | +28.8% |
| ytd | +6.0% | +1.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HCA Fundamental Analysis
HCA exhibits a solid revenue growth trajectory, with Q4 2025 revenue of $19.51 billion representing a 6.72% year-over-year increase, and a sequential quarterly trend showing consistent growth from $18.32 billion in Q1 to the Q4 figure. The growth is primarily driven by its core domestic hospital operations, with Managed Care and Other Insurers contributing $9.54 billion, indicating a diversified and stable payer mix. This steady top-line expansion supports the company's scale advantages and market position. The company is highly profitable, reporting Q4 2025 net income of $1.88 billion and a net margin of 9.62%, with a gross margin of 41.90% and an operating margin of 16.29%. Profitability metrics have shown stability, with the Q4 net margin improving from 7.86% in Q4 2024, demonstrating effective cost management and operating leverage despite industry-wide labor and inflationary pressures. The balance sheet and cash flow picture is strong, characterized by robust free cash flow generation, with TTM free cash flow of $7.69 billion. However, the debt-to-equity ratio is reported at -8.33 due to negative shareholder equity, a common feature for firms with significant share buybacks, but the interest coverage ratio of 5.56 and substantial operating cash flow provide ample capacity to service debt. The current ratio of 0.83 indicates a relatively tight liquidity position for meeting short-term obligations, though this is typical for asset-intensive healthcare operators.
Quarterly Revenue
$19.5B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.41%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HCA Overvalued?
Given HCA's substantial and consistent profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 15.88x and a forward PE of 14.89x based on estimated EPS. The modest discount of the forward multiple suggests the market anticipates stable, but not dramatically accelerating, earnings growth. Compared to sector averages, HCA's valuation presents a nuanced picture; its trailing PE of 15.88x is generally in line with or at a slight premium to many hospital peers, justified by its industry-leading scale, margins, and consistent execution. The Price-to-Sales ratio of 1.42x and EV/EBITDA of 10.05x provide additional context, indicating the market values its revenue stream and operating cash flow efficiently. Historically, the current trailing PE of 15.88x sits well below the stock's own historical highs seen in recent years, such as the 20.79x recorded in Q3 2024. This positioning suggests the stock is not at peak valuation optimism, potentially offering a more reasonable entry point within its own historical context, especially when considering its strong fundamental performance and growth trajectory.
PE
15.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HCA operates with significant financial leverage, evidenced by a debt-to-equity ratio of -8.33 and negative shareholder equity, though its strong interest coverage ratio of 5.56 mitigates near-term default risk. The current ratio of 0.83 indicates a tight liquidity position, which could strain operations if unexpected cash needs arise or if the robust TTM free cash flow of $7.69B were to decline. While revenue growth is steady at 6.72% YoY, the company's valuation premium requires this growth to be maintained, as any deceleration could trigger multiple compression.
Market & Competitive Risks: Trading at a trailing PE of 15.88x, HCA carries a valuation premium justified by its leading scale, but this makes it susceptible to sector-wide multiple compression, especially if interest rates remain elevated. The stock's high beta of 1.37 confirms its sensitivity to broader market swings, and its recent -7.78% one-month decline amid a flat market highlights this volatility. Persistent regulatory pressures on healthcare reimbursement represent an evergreen competitive and operational threat that could erode the impressive 16.29% operating margin over time.
Worst-Case Scenario: A severe scenario would involve a combination of a sharp economic downturn reducing patient volumes, coupled with adverse regulatory changes that cut reimbursement rates. This could trigger analyst downgrades, a re-rating to the lower end of the sector's PE range, and a flight from high-beta stocks. Realistic downside could see the stock retreat towards its 52-week low of $314.43, representing a potential loss of approximately -37% from the current price of $495.47. A more immediate bear-case target, based on recent support breakdowns, could be in the $430-$450 range (-9% to -13%).
FAQ
The key risks are, in order of severity: 1) Regulatory & Reimbursement Risk: Changes to government healthcare policy can directly impact revenue and margins, an evergreen threat for hospitals. 2) Financial Leverage: The debt-to-equity ratio of -8.33 indicates a leveraged balance sheet, though strong cash flow mitigates this. 3) Market Volatility: With a beta of 1.37, HCA's stock price is highly sensitive to broader market swings, as seen in its -7.78% one-month drop during a flat market. 4) Operational Execution: Maintaining the recent net margin expansion above 9% requires ongoing effective management of labor and supply costs in an inflationary environment.
The 12-month forecast for HCA is a range-bound advance with a base case target of $500-$540 (55% probability), representing modest upside from the current $495.47. The bull case (30% probability) targets $556-$600, driven by flawless execution and multiple expansion. The bear case (15% probability) sees a retreat to $430-$470 on an earnings miss or regulatory scare. The most likely scenario is the base case, where solid fundamental growth is offset by valuation constraints, leading to low-to-mid single-digit percentage returns. The key assumption is that quarterly revenue growth remains between 5-7%.
HCA stock is fairly valued. Its trailing PE of 15.88x and forward PE of 14.89x are at a moderate premium to many hospital peers, which is justified by its industry-leading scale, margins, and consistent execution. However, this valuation is well below its own historical high of 20.79x, suggesting the market is not overly optimistic. The Price-to-Sales ratio of 1.42x and EV/EBITDA of 10.05x are efficient. The current valuation implies the market expects steady mid-single-digit earnings growth but is discounting it for regulatory risks and volatility, leaving little margin for error.
HCA is a good stock for investors seeking exposure to a well-managed, cash-generative leader in the hospital sector, but timing is crucial. At its current price of $495.47 and forward PE of 14.89x, it is fairly valued, not deeply undervalued. The strong fundamentals (6.72% revenue growth, 9.62% net margin, $7.69B FCF) are compelling, but the high beta of 1.37 means it carries above-market volatility. It is a good buy for long-term investors on meaningful pullbacks (e.g., towards $470) or for those building a position gradually. Near-term traders should be cautious due to recent technical weakness.
HCA is more suitable for a long-term investment horizon of 3-5 years. Its high beta of 1.37 and sensitivity to quarterly news flow make it a challenging short-term trading vehicle, as evidenced by its recent sharp pullback. For long-term investors, the company's dominant market position, demographic tailwinds, and consistent cash generation for dividends (0.63% yield) and buybacks can compound value. A minimum holding period of 12-18 months is suggested to ride out volatility and capture the underlying earnings growth. Short-term traders should only engage with a disciplined strategy around key technical levels and earnings events.
